Tamoxifen metabolism by microsomal cytochrome P450 and flavin-containing monooxygenase

Methods in Enzymology

Volumn 272, Issue , 1996, Pages 152-163

  Kupfer, David ^a   Dehal, Shangara S ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; DIMETHYLANILINE MONOOXYGENASE; FLAVOPROTEIN; TAMOXIFEN; TAMOXIFEN DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; DIAGNOSTIC PROCEDURE; DRUG DETERMINATION; DRUG METABOLISM; ENZYME ASSAY; ENZYME BINDING; FEMALE; INCUBATION TIME; LIVER MICROSOME; MALE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ASSAY; RADIOMETRY; RAT;

ANIMALIA;

EID: 0029758139     PISSN: 00766879     EISSN: None     Source Type: Book Series    
DOI: 10.1016/s0076-6879(96)72019-0     Document Type: Article

References (54)

1. V. C. Jordan, Breast Cancer Res. Treat. 11, 197 (1988).
2. V. C. Jordan, Br. J. Pharmacol. 110, 507 (1993).
3. B. J. A. Furr and V. C. Jordan, Pharmacol. Ther. 25, 127 (1984).
4. B. Fisher and C. Redmond, J. Natl. Cancer Inst. 83, 1278 (1991).
5. M. D. Wold and V. C. Jordan, in "Antihormones in Health and Disease" (M. K. Agarwal, ed.), Vol. 19, p. 87. Karger, Basel, 1991.
6. M. A. Killackey, T. B. Hakes, and V. K. Price, Cancer Treat. Rep. 69, 237 (1985).
7. T. Fornander, B. Cedermark, A. Malteson, L. Skoog, T. Theve, J. Askergren, L. E. Rutqvist, U. Glas, C. Silversward, A. Somell, N. Wilking, and M. J. Hjolmar, Lancet 1, 117 (1989).
8. K. C. Fendel and S. J. Zimniski, Cancer Res. 52, 235 (1992).
9. G. M. Williams, M. J. Iatropoulos, M. W. Djordjevic, and O. P. Kaltenberg, Carcinogenesis (London) 14, 315 (1993).
10. S. D. Lyman and V. C. Jordan, in "Metabolism of Non-steroidal Antiestrogens in Estrogen/ Antiestrogen Action and Breast Cancer Therapy" (V. C. Jordan, ed.), p. 191. Univ. of Wisconsin Press, Madison, 1986.
11. A. B. Foster, L. J. Griggs, M. Jarman, M. S. van Maanen, and H.-R. Schulten, Biochem. Pharmacol. 29, 1977 (1980).
12. P. C. Reunitz, J. R. Bagley, and C. W. Pape, Drug Metab. Dispos. 12, 478 (1984).
13. R. McCague and A. Seago, Biochem. Pharmacol. 35, 827 (1986).
14. C. Mani, H. V. Gelboin, S. S. Park, R. Pierce, A. Parkinson, and D. Kupfer, Drug Metab. Dispos. 21, 645 (1993).
15. C. K. Lim, Z.-X. Yuan, J. H. Lamb, I. N. H. White, F. De Matteis, and L. L. Smith, Carcinogenesis (London) 15, 589 (1994).
16. G. K. Poon, B. Walter, P. E. Lonning, M. N. Holton, and R. McCague, Drug Metab. Dispos. 23, 377 (1995).
17. D. H. Phillips, P. L. Carmichael, A. Hewer, K. J. Cole, and G. K. Poon, Cancer Res. 54, 5518 (1994).
18. G. K. Poon, Y. C. Chui, R. McCague, P. E. Lonning, R. Feng, M. G. Rowlands, and M. Jarman, Drug Metab. Dispos. 21, 1119 (1993).
19. D. R. Nelson, T. Kamataki, D. J. Waxman, F. P. Guengerich, R. W. Estabrook, R. Feyereisen, F. J. Gonzalez, M. J. Coon, I. C. Gunsalus, O. Gotoh, K. Okuda, and D. W. Nebert, DNA Cell Biol. 12, 1 (1993).
20. F. Jacolot, I. Simon, P. Y. Dreano, P. Beaune, C. Riche, and F. Berthou, Biochem. Pharmacol. 41, 1911 (1991).
21. C. Mani, E. Hodgson, and D. Kupfer, Drug Metab. Dispos. 21, 657 (1993).
22. C. Mani and D. Kupfer, Cancer Res. 51, 6052 (1991).
23. X.-L. Han and J. G. Liehr, Cancer Res. 52, 1360 (1992).
24. I. N. H. White, F. de Matteis, A. Davies, L. L. Smith, C. Crofton-Sleigh, S. Venitt, A. Hewer, and D. H. Phillips, Carcinogenesis (London) 13, 2197 (1992).
25. D. N. Pathak, K. Pongracz, and W. J. Bodell, Carcinogensis (London) 16, 11 (1995).
26. C. Mani, R. Pierce, A. Parkinson, and D. Kupfer, Carcinogenesis (London) 15, 2715 (1994).
27. I. N. H. White, A. Davis, L. L. Smith, S. Dawson, and F. de Matteis, Biochem. Pharmacol. 45, 21 (1993).
28. E. F. Nuwaysir, Y. P. Dragon, C. R. Jefcoate, V. C. Jordan, and H. C. Pilot, Cancer Res. 55, 1780 (1995).
29. C. K. Lim, Z.-X. Yuan, J. H. Lamb, I. N. H. White, F. de Matteis, and L. L. Smith, Carcinogenesis (London) 15, 589 (1994).
30. S. H. Burstein and D. Kupfer, Ann. N.Y. Acad. Sci. 191, 61 (1971).
31. O. H. Lowry, N. J. Rosebrough, A. L. Farr, and R. J. Randall, J. Biol. Chem. 193, 265 (1951).
32. C. E. Stauffer, Anal. Biochem. 69, 646 (1975).
33. Because of heat lability of FMO, preincubation in the absence of NADPH should be avoided when FMO catalysis is desired.
34. M. J. Juedes, W. H. Bulger, and D. Kupfer, Drug Metab. Dispos. 15, 786 (1987).
35. W. H. Bulger, J. E. Temple, and D. Kupfer, Toxicol. Appl. Pharmacol. 68, 367 (1983).
36. D. Kupfer, C. Mani, C. A. Lee, and A. B. Rifkind, Cancer Res. 54, 3140 (1994).
37. Although an ethanolic solution of tamoxifen stored at 0-4° is essentially stable, a small amount of N-oxide is generated with time because of air exposure. It is, therefore, advisable that the stock of tamoxifen be monitored and, if necessary, purified on TLC.
38. The low level of N-oxidation of tamoxifen by chicken liver microsomes, despite the presence of considerable amount of FMO, is attributed to its restrictive active site (Dr. Daniel Ziegler, personal communication).
39. Initially, 25 IU of COMT was included in incubations; however, we later observed that there is no necessity for exogenous COMT since there is sufficient COMT in the microsomes.
40. S. A. Li, R. H. Purdy, and J. J. Li, Carcinogenesis (London) 10, 63 (1989).
41. A. R. Hoffman, S. M. Paul, and J. Axelrod, Biochem. Pharmacol. 29, 83 (1980).
42. D. Kupfer, W. H. Bulger, and A. D. Theoharides, Chem. Res. Toxicol. 3, 8 (1990).
43. S. A. Wrighton, P. Maurel, E. G. Schuetz, P. B. Watkins, B. Young, and P. S. Guzelian, Biochemistry 24, 2171 (1985).
44. 45
45. A. J. Sonderfan, M. P. Arlotto, D. R. Sutton, S. K. McMillen, and A. Parkinson, Arch. Biochem. Biophys. 255, 27 (1987).
46. 14,47
47. M. Halvorson, D. Greenway, D. Eberhart, K. Fitzgerald, and A. Parkinson, Arch. Biochem. Biophys. 277, 166 (1990).
48. F. Vignon, M.-M. Bouton, and H. Rochefort, Biochem. Biophys. Res. Commun. 146, 1502 (1987).
49. E. Coezy, J. L. Borgna, and H. Rochefort, Cancer Res. 42, 317 (1982).
50. C. Malet, A. Compel, P. Spritzer, N. Bricout, H. Yaneva, I. Mowszowicz, F. Kuttenn, and P. Mayvais-Jarvis, Cancer Res. 48, 7193 (1988).
51. A. B. Rifkind, A. Kanetoshi, J. Orlinick, J. H. Capdevila, and C. A. Lee, J. Biol. Chem. 269, 3387 (1994).
52. I. N. H. White, F. de Matteis, A. H. Gibbs, C. K. Lim, C. R. Wolf, C. Henderson, and L. L. Smith, Biochem. Pharmacol. 49, 1035 (1995).
53. K. Iwasaki, H. Noguchi, R. Kato, and R. Sato, Biochem. Biophys. Res. Commun. 77, 1143 (1977).
54. M. Sugiura, K. Iwasaki, and R. Kato, Biochem. Pharmacol. 26, 489 (1977).